First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699
A Randomised, Double-blind (Sponsor Open), Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 in Healthy Male Participants
Sponsor: GlaxoSmithKline
Terminated
The trial was terminated for strategic reasons following the emergence of new data.
Other terminated trials from GlaxoSmithKline
Other Arthritis, Rheumatoid trials with similar outcome
Listed as NCT03426995, this PHASE1 trial focuses on Arthritis, Rheumatoid and remains terminated or withdrawn. Sponsored by GlaxoSmithKline, it has been updated 12 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2022 — Mar 2022 [monthly]
Terminated PHASE1
-
Jan 2021 — Jan 2022 [monthly]
Terminated PHASE1
▶ Show 7 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Nov 2019 — Mar 2020 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Oct 2018 — Nov 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — Apr 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .